BridgeBio Pharma, Inc. — Director's Dealing 2020

Oct 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-10-01

Reporting Person: HENDERSON MICHAEL THOMAS (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-01	Common Stock	M	3255	$0.28	Acquired	271006	Direct
2020-10-01	Common Stock	M	6745	$1.05	Acquired	277751	Direct
2020-10-01	Common Stock	S	4495	$38.2855	Disposed	273256	Direct
2020-10-01	Common Stock	S	5505	$39.2822	Disposed	267751	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-01	Stock Option (Right to Buy)	$0.28	M	2236	Disposed	2027-11-13	Common Stock (2236)	Direct
2020-10-01	Stock Option (Right to Buy)	$0.28	M	1019	Disposed	2028-05-07	Common Stock (1019)	Direct
2020-10-01	Stock Option (Right to Buy)	$1.05	M	6745	Disposed	2029-09-24	Common Stock (6745)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020.

F2: Represents the weighted average sale price of the shares sold from $37.74 to $38.72 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.

F3: Represents the weighted average sale price of the shares sold from $38.81 to $39.71 per share.